WO2006036962A3 - Compositions and methods for modulating tissue regeneration and chemotactic responses - Google Patents

Compositions and methods for modulating tissue regeneration and chemotactic responses Download PDF

Info

Publication number
WO2006036962A3
WO2006036962A3 PCT/US2005/034593 US2005034593W WO2006036962A3 WO 2006036962 A3 WO2006036962 A3 WO 2006036962A3 US 2005034593 W US2005034593 W US 2005034593W WO 2006036962 A3 WO2006036962 A3 WO 2006036962A3
Authority
WO
WIPO (PCT)
Prior art keywords
ccn3
methods
compositions
discloses
wound repair
Prior art date
Application number
PCT/US2005/034593
Other languages
French (fr)
Other versions
WO2006036962A2 (en
Inventor
Lester F Lau
Original Assignee
Lester F Lau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lester F Lau filed Critical Lester F Lau
Priority to CA002582224A priority Critical patent/CA2582224A1/en
Publication of WO2006036962A2 publication Critical patent/WO2006036962A2/en
Publication of WO2006036962A3 publication Critical patent/WO2006036962A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention relates to the fields of monitoring and modulating wound healing responses, controlling stem cell homing in vivo and tissue construction in vitro. Specifically, the present specification discloses that monitoring CCN3 expression during wound healing can be used for diagnostic purposes of detecting abnormal wound repair. The compositions blocking CCN3 activity for the methods of inhibiting wound repair are also disclosed, as well as compositions of expressing CCN3 polypeptide or its functional fragment for the methods of stimulating wound repair. Furthermore, the instant specification also discloses that CCN3 can be added to stem cells to retain the cells in a particular area and, therefore, accomplish stem cell homing. Finally, the instant invention also discloses that CCN3 polypeptide can be used for controlling cell migration during tissue construction in vitro
PCT/US2005/034593 2004-09-28 2005-09-28 Compositions and methods for modulating tissue regeneration and chemotactic responses WO2006036962A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002582224A CA2582224A1 (en) 2004-09-28 2005-09-28 Compositions and methods for modulating tissue regeneration and chemotactic responses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61521304P 2004-09-28 2004-09-28
US60/615,213 2004-09-28

Publications (2)

Publication Number Publication Date
WO2006036962A2 WO2006036962A2 (en) 2006-04-06
WO2006036962A3 true WO2006036962A3 (en) 2007-08-23

Family

ID=36119532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/034593 WO2006036962A2 (en) 2004-09-28 2005-09-28 Compositions and methods for modulating tissue regeneration and chemotactic responses

Country Status (2)

Country Link
CA (1) CA2582224A1 (en)
WO (1) WO2006036962A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7780949B2 (en) 2005-01-10 2010-08-24 Rosalind Franklin University Of Medicine And Science Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases
DK1841316T3 (en) * 2005-01-10 2011-08-08 Univ Rosalind Franklin Medicine & Science CCN3 protein for use in the treatment and diagnosis of kidney disease
JP5939584B2 (en) * 2010-04-02 2016-06-22 ロザリンド フランクリン ユニバーシティー オブ メディスン アンド サイエンス Therapeutic CCN3 peptides and analogs thereof
US9114112B2 (en) * 2010-04-02 2015-08-25 Rosalind Franklin University Of Medicine And Science CCN3 and CCN3 peptides and analogs thereof for therapeutic uses
WO2011134063A1 (en) * 2010-04-26 2011-11-03 UNIVERSITé LAVAL Ccn3 and uses thereof against metabolic syndrome- associated disorders
US10028906B2 (en) 2016-03-22 2018-07-24 Rosalind Franklin University Of Medicine And Science Method and kit for treating a solid tumor and associated desmoplasia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178332A1 (en) * 2005-01-10 2006-08-10 Riser Bruce L Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060178332A1 (en) * 2005-01-10 2006-08-10 Riser Bruce L Regulation of CCN2 by CCN3 and its therapeutic and diagnostic potential in fibrosis, sclerosis and other diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LEU ET AL.: "Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alphabeta3 and alphabeta1 in human umbilical vein endothelial cells", J. BIOL. CHEM., vol. 277, no. 48, 29 November 2002 (2002-11-29), pages 46248 - 46255, XP003017018 *
LIN ET AL.: "Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing", J. BIOL. CHEM., vol. 280, no. 9, 4 March 2005 (2005-03-04), pages 8229 - 8237, XP003017017 *
PERBAL B.: "The CCN3 Protein and Cancer", ADV. EXP. MED. BIOL., vol. 587, 2006, pages 23 - 40 *

Also Published As

Publication number Publication date
CA2582224A1 (en) 2006-04-06
WO2006036962A2 (en) 2006-04-06

Similar Documents

Publication Publication Date Title
WO2006036962A3 (en) Compositions and methods for modulating tissue regeneration and chemotactic responses
WO2005099715A3 (en) Treatment of ophthalmic conditions with mineralcorticoids
WO2006073671A8 (en) Protein activity modification
WO2011026132A8 (en) Methods and compositions for the inhibition of transplant rejection
WO2011053783A3 (en) Ax213 and ax132 pcsk9 antagonists and variants
IL191771A0 (en) Improved composition for collecting and preserving placental stem cells and methods of using the composition
WO2008063382A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008057458A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
MX2010008206A (en) Methods and compositions using klotho-fgf fusion polypeptides.
WO2009136291A3 (en) Cellular extracts
WO2008013737A3 (en) Compositions for reprogramming a cell and uses therefor
WO2008108803A3 (en) Immune cell biosensors and methods of using same
WO2006081435A3 (en) Method of providing readily available cellular material derived from cord blood, and a composition thereof
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2005119899A3 (en) Use of lacritin in promoting ocular cell survival
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
WO2008013985A3 (en) Use of heat shock activators for tissue regeneration
WO2008073392A3 (en) Compositions and methods for cardiac tissue protection and regeneration
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
WO2006114105A3 (en) Use of modified factor vii for treating bleeding
WO2008080623A3 (en) Neutralization of cd95 activity blocks invasion of glioblastoma cells in vivo
WO2008127680A3 (en) Diagnosis and treatment of diseases caused by misfolded proteins
WO2006135493A3 (en) A composition for wound healing and use thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2007533740

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2582224

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: JP

122 Ep: pct application non-entry in european phase

Ref document number: 05802777

Country of ref document: EP

Kind code of ref document: A2